Episodit
-
Guest: Kelly Gwathmey, MD
ALS can take up to a year to diagnose, but researchers are hard at work trying to find ways to minimize diagnostic delays and errors. One such solution is the Rapid Access ALS Clinic, where patients were diagnosed an average of two months sooner. Here to talk about this work is Dr. Kelly Gwathmey, Professor of Neurology at the Virginia Commonwealth University School of Medicine who presented a session on this topic at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting.
-
Host: Ashley Baker, MSN, PMHNP
Guest: Stacy Finkbeiner, PhD
The IMPACT-TD Registry is an ongoing, real-world observational study that aims to better understand the multidimensional impacts of tardive dyskinesia (TD) on patients’ lives. To achieve this goal, the IMPACT-TD Scale was developed and used by clinicians involved with the study, and now the results from the interim analysis are available. Joining psychiatric nurse practitioner Ashley Baker to share the key findings on TD’s impact from the clinician perspective is Dr. Stacy Finkbeiner, U.S. Medical Director at Teva Pharmaceuticals.
-
Puuttuva jakso?
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Stacy Finkbeiner, PhD
Guest: Bill Cote
To gain insights into how tardive dyskinesia (TD) can impact the physical, psychological, social, and professional lives of patients, the IMPACT-TD Registry incorporated feedback from patients and caregivers to create an effective questionnaire. These patient-reported measures are key to the overall management of TD as they enable us to better understand how TD affects each individual. To learn more about the patient-reported outcomes from the IMPACT-TD Registry, Dr. Charles Turck speaks with Dr. Stacy Finkbeiner and Mr. Bill Cote. Dr. Finkbeiner is US Medical Director at Teva Pharmaceuticals, and Mr. Cote is the Senior Director of the National Organization for Tardive Dyskinesia.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew J. Cutler, MD
Guest: Michelle Scargle, MD
Tardive dyskinesia is quite common as up to 20 percent of patients may develop this hyperkinetic movement disorder. But despite its prevalence, there are many barriers that can keep us from screening patients for tardive dyskinesia. To learn more about these barriers and how we can overcome them to optimize our screening approach, Dr. Charles Turck speaks with Drs. Andrew Cutler and Michelle Scargle. Dr. Cutler is a Clinical Associate Professor in the Department of Psychiatry and Behavioral Sciences at the SUNY Upstate Medical University in Syracuse, New York, and Dr. Scargle is the Chief Psychiatrist at Concord Health in Clearwater, Florida.
-
Host: Ashley Baker, MSN, PMHNP
Guest: Richard Jackson, MD
The IMPACT-TD scale enables us to evaluate the effects of tardive dyskinesia across four key domains: psychological/psychiatric, social, physical, and vocational/educational/recreational. By using this assessment tool, we can not only gain a deeper understanding of how our patients are impacted by tardive dyskinesia, but it can also foster better communication and treatment outcomes. To learn more, psychiatric nurse practitioner Ashley Baker speaks with Dr. Richard Jackson, Associate Clinical Professor at the Oakland Beaumont University School of Medicine and an Assistant Clinical Professor at the University of Michigan School of Medicine.
-
Guest: John F. Brandsema, MD
Between 60 and 70 percent of patients with Duchenne muscular dystrophy (DMD) also have a diagnosable neurobehavioral phenotype like autism, ADHD, and anxiety. Here to talk about these common neurobehavioral issues in patients with DMD and how we can manage them is Dr. John Brandsema, Neuromuscular Section Head at the Children’s Hospital of Philadelphia.
-
Guest: John F. Brandsema, MD
As patients with Duchenne muscular dystrophy (DMD) age, their treatment regimens, considerations, and goals change. That’s why Dr. John Brandsema is here to talk about how we can best treat and support patients with DMD throughout their entire care journey. Dr. Brandsema is the Neuromuscular Section Head at the Children’s Hospital of Philadelphia.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John F. Brandsema, MD
The gene therapy delandistrogene moxeparvovec was recently approved for patients with Duchenne muscular dystrophy (DMD) who are at least 4 years old. This expanded approval is based on the efficacy and safety results from the EMBARK trial. Joining Dr. Charles Turck to break down those key findings and the implications of this advancement in DMD treatment is Dr. John Brandsema. Dr. Brandsema is the Neuromuscular Section Head at the Children’s Hospital of Philadelphia, where one of the clinical trials for this gene therapy took place.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jasmohan Bajaj, MD
Around 50 percent of people with cirrhosis have hepatic encephalopathy, which means some kind of brain dysfunction. As these patients age, it gets more and more difficult to differentiate between hepatic encephalopathy and dementia, which is why two recent studies sought to uncover how many patients with dementia have undiagnosed cirrhosis. According to the findings, the rate of undiagnosed cirrhosis and hepatic encephalopathy could be as high as 10‒13 percent. Joining Dr. Charles Turck to share further details about the studies, findings, and implications is Dr. Jasmohan Bajaj, Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Dr. Robert J. Shmookler Reis, PhD
Guest: Dr. Srinivas Ayyadevara, PhD
Numerous factors could predispose patients to the progression of mild cognitive impairment or dementia and Alzheimer’s disease. Fortunately, a recent study found that a cholesterol-lowering medication called ezetimibe might help reduce the risk of Alzheimer’s disease progression and related dementias. To learn about the methods and key findings of the study, join Dr. Charles Turck as he takes a deep dive with Dr. Robert Reis, Professor and Researcher at the University of Arkansas for Medical Sciences’ Institute on Aging College of Medicine and Research Career Scientist at the Central Arkansas Veterans Healthcare System’s Geriatric Research, Education and Clinical Center, and Dr. Srini Ayyadevara, Associate Professor at the UAMS Institute on Aging College of Medicine and is a Research Health Scientist at the Central Arkansas VA’s GREC Center.
-
Host: Ashley Baker, MSN, PMHNP
Guest: Istvan Mody, PhD
The objective of this study around Alzheimer’s disease was to enhance oscillations in laying down memory traces and cognition. Using mice, the human APOE 4 gene was inserted into them, so they replicated similar events that take place in Alzheimer’s patients, and other mice were treated with DDL-920. The hope is to move on to human patients and to have a big impact on improving Alzheimer’s patient's life, cognition, and memory. To learn more, join Psychiatric Nurse Practitioner Ashley Baker as she speaks with Dr. Istvan Mody, Professor of Neurology and Physiology at UCLA Health and recipient of the J. Allyn Taylor International Prize in Medicine in 2018.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nadia Merchant, MD
Guest: Melody Shi, MD
Guest: Despoina Galetaki, MD
Steroids are one of the main treatments for patients with Duchenne muscular dystrophy (DMD), but prolonged steroid use can come with many endocrine side effects, like weight gain, insulin resistance, and adrenal insufficiency. To learn more about these endocrine complications and surveillance, a recent survey was conducted, and here to share the results with Dr. Charles Turck are study authors Drs. Nadia Merchant, Melody Shi, and Despoina Galetaki.
-
Guest: Mar Tintore, MD
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 annual meeting is celebrating its 40th anniversary in Copenhagen, Denmark. 9,000 delegates from all over the world are expected to attend this multiday event, which will include keynote lectures, poster sessions, and selected scientific and educational sessions, as well as plenty of philanthropic and networking opportunities and more. Tune in for a brief overview with Dr. Mar Tintoré, President of ECTRIMS and Clinical Coordinator of the Multiple Sclerosis Centre of Catalonia Cemcat at the Hospital Vall d’Hebron in Barcelona, Spain.
-
Guest: Mar Tintore, MD
A special guest will be joining the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 annual meeting on opening day. To learn more about the impact ECTRIMS has had on multiple sclerosis patients over the last 40 years, tune in with Dr. Mar Tintoré, President of ECTRIMS and Clinical Coordinator of the Multiple Sclerosis Centre of Catalonia Cemcat at the Hospital Vall d’Hebron in Barcelona, Spain.
-
Guest: Mar Tintore, MD
At this year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, learn about a presentation on the new criteria for diagnosing multiple sclerosis (MS) patients with Dr. Mar Tintoré, President of ECTRIMS and Clinical Coordinator of the Multiple Sclerosis Centre of Catalonia Cemcat at the Hospital Vall d’Hebron in Barcelona, Spain.
-
Guest: Kathleen Nadeau, PhD
It’s important to be aware of the different ways ADHD impacts girls and women compared to boys and men, which is why Dr. Kathleen Nadeau is here to help shed light on those differences. Dr. Nadeau is the Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.
-
Host: Ashley Baker, MSN, PMHNP
Guest: Kathleen Nadeau, PhD
Girls and women with ADHD are often underdiagnosed and undertreated compared to boys and men, which puts them at risk of serious issues like unplanned pregnancies, cigarette smoking, and even anxiety and depression. To help us better identify and manage girls and women with ADHD, psychiatric nurse practitioner Ashley Baker speaks with Dr. Kathleen Nadeau, Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kay Davies, PhD, DBE FMedSci FRS
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by the progressive loss of muscle, and it primarily occurs in young boys. And since there’s currently no cure, recent therapeutic advancements are aimed at improving symptoms and patient’s quality of life. Dive in to review the therapeutic landscape with Dr. Charles Turck as he’s joined by Dr. Kay Davies, who’sDr Lee's Professor of Anatomy Emeritus at the University of Oxford.
-
Host: Craig M. McDonald, MD
Guest: Crystal Proud, MD
Guest: Aravindhan Veerapandiyan, MD
There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies.
-
Host: Ashley Baker, MSN, PMHNP
Guest: David Goodman, MD, LFAPA
ADHD is a lifelong disorder, but its symptoms like memory and concentration difficulties can often be misinterpreted as normal functions of aging. So to help address this misunderstanding, psychiatric nurse practitioner Ashley Baker speaks with Dr. David Goodman about essential diagnostic and treatment strategies for older adults with ADHD. Dr. Goodman is the Director of the Adult Attention Deficit Disorder Center of Maryland.
- Näytä enemmän
